SlideShare une entreprise Scribd logo
1  sur  91
Télécharger pour lire hors ligne
Basic Infertility Investigation
Prof.Salah Roshdy,MD
Prof. of Obstetrics & Gynecology
Sohag University
2018
Objectives
 know definitions of primary and secondary
infertility
 • understand the causes of infertility
 • know the initial investigations of the
infertile couple
 Investigate male factor
 • Test for ovulation
 • Test for tubal patency
 • Investigation role of laparoscopy and
hysteroscopy
INTRODUCTION
 Infertility is a common condition with
important psychologic, economic,
demographic, and medical
implications.
 Infertility is a unique medical condition
because it involves a couple, rather
than a single individual.
DEFINITIONS
 It is defined as inability of a couple to
conceive after 12 months of regular
intercourse without use of contraception in
women less than 35 years of age; and
 after six months in women 35 years
and older.
 Some clinicians use the term subfertility
to describe this failure to conceive unless
the couple has been proven to be sterile.
Primary infertility
is the term used to describe
a couple that has never
been able to conceive ,after
at least 1 year of
unprotected intercourse.
Secondary infertility
Secondary infertility describes
couples who have previously
been pregnant at least once,
but have not been able to
achieve another pregnancy.
NORMAL FERTILITY
 A study examined the number of months to
conception in 5574 normal women who had
unprotected intercourse and who became
pregnant . Eighty-five percent of the women
conceived within 12 months.
 Five to 15 percent of apparently normal couples
will conceive in the second 12 months of
attempted conception so that after 24 months ,
95 percent of couples will have conceived.
Natural Cumulative Pregnancy
Rate
1
2
3
4
5
6
7
8
9
10
11
12
24
0
10
20
30
40
50
60
70
80
90
1 2 3 4 5 6 7 8 9 10 11 12 24
% pregnant/month
Months of trying
PREVALENCE Of INFERTILITY
ranges from 12 to 18 %.
women 15 to 34 years (7.3 to
9.1 percent)
 35 to 39 years (25 percent)
40 to 44 years (30 percent).
Causes of Infertility
 The World Health Organization (WHO) task
force on Diagnosis and Treatment of Infertility
performed a study of 8500 infertile couples and
utilized standard diagnostic criteria to determine
the medical conditions contributing to infertility.
 female factor : 38 %
 Male factor : 20%
 Both : 27%
 UI : 15%
Male factor
 1-Endocrine and systemic disorders
(hypogonadotropic hypogonadism)2-5%
 A-Congenital disorders
 B- Acquired disorders
 C-Systemic disorders:
2-Primary testicular defects in
spermatogenesis(65 to 80 %)
 A-Congenital disorders;
 B-Acquired disorders
 C-Systemic illness
 D-Genetic causes of dysspermatogenesis
 3-Sperm transport disorders(5%)
 4-Sexual dysfunction:
 5-Idiopathic male infertility(10-20%)
Basic infertility inves,Prof.S.Roshdy
1-OVARY
 Ovulatory disorders:
Infrequent ovulation (oligoovulation)
or
absent ovulation (anovulation).
Oocyte aging:
 Ovarian cysts:
An
Anovulation
Hypothalamic
Pituitary
Ovarian
Physiologic
• Adolescence
• Perimenopause
• Lactation
• Pregnancy
Hyperandrogenic
• PCOS
• CAH
• Androgen tumors
Hypothalamic Dysfunction
• Primary hypothalamic
• Anorexia Nervosa
• Extreme exercise
• Hyperprolactinemia
• Thyroid disease
• Primary pituitary disease
• Medications
• Premature ovarian failure
• Iatrogenic (chemo/rad)
Hyperinsulinemic
• PCOS
• DM/Pre-diabetes
• Metabolic syndrome
• Obesity
Endometrial
W H O classification of
anovulation
LHRH
FSHLH
Hypothalamo-
pituitary
WHO Type 1:
Hypogonadotropic
hypogonadal anovulation
(hypothalamic
amenorrhea):
Anovulation WHO Type 2:
Normogonadotropic
normoestrogenic
anovulation
Ovarian failure WHO Type 3:
Hypergonadotropic
hypoestrogenic
anovulation:
The Clues
Hot flushes
Irregular/absent periods
Short cycle
Amenorrhoea
Weight loss/Exercise/Stress
Drug-induced
Other disease
LHRH
FSHLH
Irregular menses
Weight gain
PCOS signs/symptoms
 NIH Criteria 1990:
 Menstrual irregularity due to
anovulation or oligo-ovulation
 Evidence of clinical or biochemical
hyperandrogenism
 Hirsutism, acne, male pattern baldness
 High serum androgen levels
 Exclusion of other causes (CAH,
tumors, hyperprolactinemia)
PCOS
 Rotterdam Criteria (2 out of 3)2003:
 Menstrual irregularity due to
anovulation oligo-ovulation
 Evidence of clinical or biochemical
hyperandrogenism
 Polycystic ovaries by US
 presence of 12 or more follicles in each ovary
measuring 2 to 9 mm in diameter and/or increased
ovarian volume.
* In addition, other etiologies (congenital adrenal
hyperplasias, androgen-secreting tumors, Cushing's
syndrome) must be excluded.
 AES criteria 2006:
Presence of three features
 Androgen excess (clinical and/or
biochemical hyperandrogenism)
 Ovarian dysfunction (oligo-anovulation
and/or polycystic ovarian morphology)
 Exclusion of other androgen excess or
ovulatory disorders
Basic infertility inves,Prof.S.Roshdy
Uterus
Tube
Anatomic Features of
the Polycystic Ovary
2-FALLOPIAN TUBE
ABNORMALITIES/PELVIC ADHESIONS
 Tubal disease and pelvic adhesions
prevent normal transport of the oocyte and
sperm through the fallopian tube.
 PID
 Severe endometriosis
 Previous surgery or non-tubal infection
(eg, appendicitis, inflammatory bowel
disease),
 Pelvic TB
Hydrosalpinx:
 Women with distal tubal obstruction may
develop hydrosalpinges, which decrease
the success rate of (IVF). In addition to
obstruction to sperm migration,
hydrosalpinges appear to reduce fertility
by
 retrograde flow of tubal contents into the
endometrial cavity, which creates a hostile
environment to implantation of an embryo.
Hydrosalpinx:
 Treatment of hydrosalpinx before IVF
Negative effect on PR, IR, early pregnancy
loss & LBR. LBR are reduced by 50%
 WHY?
 The fluid of hydrosalpinx:
 1.Mechanical barrier to implantation: embryo to
float
 2.Deficient to support the developing embryo
 3.Toxic to the developing embryo
Hydrosalpinx:
 There is good evidence for
recommending :
 laparoscopic salpingectomy or
 proximal tubal occlusion
Classification of Tubal disease
 British Fertility Society
 Minor
 Proximal occlusion without tubal fibrosis
 Distal occlusion without tubal distension
 Healthy mucosal appearance at HSG,
salpingoscopy
 Flimsy peritubal/ovarian adhesions.
 Intermediate
 Unilateral severe tubal damage
 Limited dense adhesions of tubes & ovaries
 Severe
 Bilateral severe tubal damage
 Extensive tubal fibrosis
 Tubal distension >1.5 cm
 Abnormal mucosal appearance
 Bipolar occlusion
 Extensive dense adhesion
3-UTERUS
 Impaired implantation, either mechanical or due
to reduced endometrial receptivity, are the basis
of uterine causes of infertility
 Uterine leiomyomata:A meta-analysis showed
 that only leiomyomata with a submucosal or
intracavitary component were associated with
lower pregnancy and implantation rates.
 The likely mechanism is inhibition to normal
implantation.
 Uterine anomalies; Uterine abnormalities are
thought to cause infertility by interfering with
normal implantation. Müllerian anomalies are a
significant cause of (RPL), with the septate
uterus associated with the poorest reproductive
outcome .
 Other structural abnormalities associated with
infertility include endometrial polyps, and
synechiae from prior pregnancyrelated
curettage.
ENDOMETRIOSIS
Mechanisms which decrease fertility in women
with endometriosis include
 Anatomic distortion from pelvic adhesions,
damage to ovarian tissue by endometrioma
formation and surgical resection,
 and the production of substances such as
cytokines and growth factors which impair the
normal processes of ovulation, fertilization, and
implantation.
4-CERVICAL FACTORS
 Normal midcycle cervical mucus
facilitates the transport of sperm.
 Congenital malformations and trauma
to the cervix (including surgery) may
result in stenosis and inability of the
cervix to produce normal mucus,
thereby impairing fertility.
5-UNEXPLAINED
 Unexplained infertility is the
diagnosis given to couples after a
thorough evaluation has not revealed
a cause.
 Many cases of unexplained infertility
may be due to small contributions
from multiple factors.
When To start Workup
( investigations)?
 An infertility evaluation is usually initiated after
one year of regular unprotected intercourse in
women under age 35 years and after six months
of unprotected intercourse in women age 35
years and older.
 However, the evaluation may be initiated sooner
in women with
 irregular menstrual cycles or endometriosis,
 a history of PID,
 or reproductive tract malformations.
The Most Important
Factor in the
Evaluation of the
Infertile Couple Is:
History
From: The diagnosis of male infertility: an analysis of the evidence to support the development of global WHO guidance—
challenges and future research opportunities
Hum Reprod Update. 2017;23(6):660-680. doi:10.1093/humupd/dmx021
Hum Reprod Update | © The Author 2017. Published by Oxford University Press on behalf of the European Society of Human Reproduction
and Embryology.This is an Open Access article distributed under the terms of the Creative Commons Attribution License
(http://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the
History-General
 Both couples should be present
 Age
 Previous pregnancies by each partner
 Duration of infertility
 Sexual history
 Frequency and timing of intercourse
 Use of lubricants
 Impotence, dyspareunia
 Contraceptive history
History-Female
 Previous female pelvic surgery
 PID
 Appendicitis
 IUD use
 Ectopic pregnancy history
 Endometriosis
 Leiomyoma
History-Female
 Irregular menses, amenorrhea, detailed
menstrual history
 Molimina
 Vasomotor symptoms
 Changes of hair growth.breast discharge
 Stress
 Weight changes
 Exercise-drug –radiation -chemotherapy
 Cervical and uterine surgery
Physical Exam-Female
 Thyroid exam
 BMI
 Hair distribution
 Galactorrhea
 Scar in the abdomen
 Pelvic masses
 Uterosacral nodularity
 Abdominopelvic tenderness
 Uterine enlargement
 Uterine mobility
 Cervical abnormalities
 Abnormal vaginal discharge
 Very long list of tests, have been
advocated to assist in
determining the cause of the
infertility in the diagnostic
evaluation of infertile couple.
 The necessity and cost effectiveness
of performing many of these tests and
correcting the abnormalities found by
them have not been demonstrated.
1-Investigations of Male Factor
 Conventional semen analysis
 Computer- assisted sperm analysis (CASA)
 A variety of sperm function tests
- The acrosome reaction test
- Hypo-osmotic swelling test
- Measurement of generation of Reactive oxygen species
- Sperm capacitation assays
- Hemizona-binding assay
- Hamster penetration test
- Human sperm-zona penetration assay
 A variety of imaging techniques for detection of
varicocele
Semen Analysis
 Semen analysis is the key laboratory
assessment of the male partner of an infertile
couple.
 The standard semen analysis consists of the
following:
 Semen volume and pH
 ● Microscopy for
• Sperm concentration, count, motility, and
morphology • Debris and agglutination
• Leukocyte count• Immature germ cells
Semen Analysis
 The semen sample should be collected
after two to seven days ejaculatory
abstinence.
 If possible, the patient should collect the
sample by masturbation at the doctor's
office. If not possible, then the sample may
be
 collected at home and delivered to the
laboratory within an hour of collection.
Basic infertility inves,Prof.S.Roshdy
Basic infertility inves,Prof.S.Roshdy
2-Assessment of ovulation
 Basal body temperature
 Urine LH kits
 Mid luteal serum progesterone
 Routine hormonal profile: FSH, LH, Prolactin,TSH
 Endometrial biopsy
 Serial pelvic Ultrasonography.
 A variety of tests for assessment of ovarian reserve
such as D3 FSH & E2, Inhibin B, Clomid challenge test,
TVS for ovarian volume, antral follicle count and
Stromal blood flow.
Evidence of ovulation:
 1. Menstrual history of regular cycles.
 2. Serum progesterone in the mid-luteal
phase of their cycle (day 21 of a 28-day
cycle) even if they have regular menstrual
cycles.
 3. Serum gonadotrophins ( FSH & LH) on
Day2-3 especially in irregular periods.
 (N.B.: No role for basal body temperature
charts)
Further investigations
 Ovarian reserve
 -More important in >35 years old, suspected
ovarian failure and to detect response to
ovulation induction.
 1. Total antral follicle count.
 2. AMH of less than or equal to 5.4 pmol/l for a
low response and greater than or equal to 25.0
pmol/l for a high response
 3. FSH greater than 8.9 IU/l for a low response
and less than 4 IU/l for a high response.
D 3 FSH
 Both the day 3 FSH level and the CCCT,
which is a provocative test for
measurement of FSH, are widely used for
screening ovarian reserve.
 The CCCT involves oral administration of
100 mg clomiphene citrate on cycle days 5
through 9 with measurement of day 3 and
day 10 FSH levels and day 3 estradiol
level.
 A value less than 10 mIU/mL suggestive of
adequate ovarian reserve.
Antral follicle count (AFC)
 Ultrasound examination can be used to
determine the number of antral follicles (defined
as follicles measuring 2 to 10 mm in diameter).
On transvaginal ultrasound,
 The ovaries are visualized in their transverse
and longitudinal planes and the antral follicles
are counted and measured; the size of the
follicle is the mean of two perpendicular
diameters, one of which should be the largest
dimension of each follicle
AFC
 A low AFC ranging from <4 to 10 antral
follicles between days two and four of a
regular menstrual cycle suggests poor
ovarian reserve.
 Although AFC is a good predictor of
ovarian reserve and response,
 It is less predictive of oocyte quality,the
ability to conceive with IVF, and pregnancy
outcome.
Basic infertility inves,Prof.S.Roshdy
Antimüllerian hormone (AMH)
 is expressed by the small (<8 mm) preantral and
early antral follicles. The AMH level reflects the size
of the primordial follicle pool, and may be the best
biochemical marker of ovarian function across an
array of clinical situations.
 The AMH level appears to be an early, reliable, direct
indicator of declining ovarian function.
 AMH level correlates with the number of oocytes
retrieved after stimulation, and is the best biomarker
for predicting poor and excessive ovarian response.
AMH
 Unlike the day 3 FSH, AMH can be
measured anytime during the menstrual
cycle.
 AMH <0.5 ng/mL predicts reduced ovarian
reserve with less than three follicles in an
IVF cycle
 ● AMH <1.0 ng/mL predicts baseline
ovarian reserve with a likelihood of limited
eggs at retrieval.
AMH
 ● AMH >1.0 ng/mL but <3.5 ng/mL
suggests a good response to stimulation
 AMH >3.5 ng/mL predicts a vigorous
response to ovarian stimulation and
caution should be exercised in order to
avoid ovarian hyperstimulation syndrome.
Basic infertility inves,Prof.S.Roshdy
No evidence for:
 - ovarian volume
 - ovarian blood flow
 - inhibin B
 -estradiol (E2)
3-Investigations of tubal factor
 Hysterosalpingography (HSG)
 Hysterosalpingo-contrast sonography
(HyCoSy)
 Laparoscopy with chromotubation
 Hydrolaparoscopy.
 Fluoroscopic/hysteroscopic-
selective tubal cannulation.
 Falloposcopy
Assessment of the uterine cavity
 Modalities to assess the uterine cavity
include :
 Saline Infusion Sono-
hysterography (SIS)
 Three dimensional sonography
 Hysterosalpingography (HSG)
 Hysteroscopy
Laparoscopy as a diagnostic tool in
infertility has diminished markedly
 Today, we rarely perform diagnostic laparoscopy in
infertile women. (Tulandi, 2017)
 1.The benefit of diagnostic laparoscopy with no risk
factors for intra-abdominal adhesions: small.
 2.Treatment of stage I or II endometriosis: small
increase in PR.
 3.Alternative treatments of infertility are available
 Superovulationwith IUI
 IVF.
Indications
 1.Abnormal HSG or US
 2.Young women with history or symptoms
suggestive of pelvic disease. Even if HSG
indicates patency in one or both tubes
 .A history of PID,
 .Ectopic pregnancy.
 .Pelvic surgery.
 .Chronic pelvic pain
 . Current dysmenorrhea, pelvic pain, or deep
dyspareunia; previous complicated appendicitis
Indications
 3. Three cycles of super ovulation with IUI are
unsuccessful.
 4. After failed IVF
 -Laparoscopy after failed IVF:(Littman et al.,
2005).
 Pathology in 50%
 endometriosis or adhesions
 No RCTs have confirmed this rate.
TESTS OF LIMITED CLINICAL
UTILITY
 PCT for assessment of the cervical factor.
 Chlamydia trachomatis antibodies .
 Endometrial biopsy
 Basal body temperature records
 Zonafree hamster oocyte penetration test
 Mycoplasma cultures
 Testing for antibodies; antiphospholipid, antisperm,
antinuclear, and antithyroid antibodies.
 Karyotype
Controversies
 Lack of agreement exists among
trained infertility specialists with regard
to prognostic utility as well as criteria of
normality of many of these tests?
 There is no consensus on which tests
are essential before reaching the exact
diagnosis ?
Investigations of infertile couple
Evidence Medicine Based Era
National Evidence-Based Clinical Guidelines
“Assessment and treatment for people with fertility problems
developed by the National Collaborating Centre for
Women and Children's Health on behalf of
the National Institutefor Clinical Excellence (NICE)”
February 2004
Grading – Evidence Based Recommendations
A
recommendation
I evidence
B
recommendation
II evidence
C
recommendation
III evidence
D
recommendation
IV evidence
I a- meta-analysis
of RCTs trials,
I b- at least one
RCT.
II a - at least one
controlled study
without
randomization
II b - at least one
other type of
quasi-
experimental
study
non-experimental
descriptive
studies, such as
comparative
studies,
correlation
studies and case
control studies
from expert
committee reports
or opinions and/or
clinical experience
of respected
authorities
• GPP Good practice point : The view of the Guideline Development Group
•The design of a quasi-experiment relates to a particular type of experiment or other study in which one has little or no control over the
allocation of the treatments or other factors being studied.
1-Semen analysis
• CASA is not superior to conventional
semen analysis (Grade A)
• Screening for antisperm antibodies
should not be offered because there is
no evidence of effective treatment to
improve fertility. (GPP)
What To Do if Semen analysis Is
Abnormal?
 Repeat confirmatory test ( 3 months after
the initial analysis & ttt). (Grade B).
 If azoospermia or severe oligozoospermia ,
repeat test as soon as possible. (GPP)
Where & When Testicular Biopsy
(TB) be done In Azoospermia?
TB should be performed only in a
tertiary service where there are
facilities for
 Sperm recovery ,
 Cryopreservation and
 ART( C )
2-Assessment of Ovulation
 Women with regular monthly menstrual
cycles are likely to be ovulating. (Grade
B)
 The use of basal body temperature
charts to confirm ovulation does not
reliably predict ovulation and is not
recommended. (Grade B)
Assessment of Ovulation
 Women with regular menstrual cycles and
more than 1 year’s infertility are offered a
blood test to measure serum progesterone
in the mid-luteal phase of their cycle (day
21 of a 28-day cycle) to confirm ovulation.
(Grade B)
Assessment of Ovulation
 Ovulation is most easily documented by a
midluteal phase serum progesterone level,
which should be obtained approximately one
week before the expected menses.
 For a typical 28day cycle, the test would be
obtained on day 21. A progesterone level >3
ng/mL is evidence of recent ovulation.
Assessment of Ovulation
 Women with irregular menstrual cycles
should be offered a blood test to measure
serum FSH & LH (GPP).
 Blood test for prolactin should only be
offered to women who have an ovulatory
disorder, galactorrhoea or a pituitary
tumor. (Grade C)
Assessment of Ovulation
 Tests of ovarian reserve currently have limited
sensitivity and specificity in predicting fertility.
However, women who have high levels of
gonadotrophins should be informed that they
are likely to have reduced fertility. (Grade C)
 The value of assessing ovarian reserve using
Inhibin B is uncertain and is therefore not
recommended. (Grade C)
Assessment of Ovulation
 Women with possible fertility problems are no
more likely than the general population to have
thyroid disease and the routine measurement of
thyroid function should not be offered.
 Estimation of thyroid function should be
confined to women with symptoms of thyroid
disease. (Grade C).
Assessment of Ovulation
 Women should not be offered an
endometrial biopsy to evaluate the luteal
phase as part of the investigation of
fertility problems because there is no
evidence that medical treatment of luteal
phase defect improves pregnancy rates
(Grade B).
3-Assessment of tubal factor
 Women who are not known to have co-
morbidities should be offered HSG to
screen for tubal occlusion because this
is a reliable test for ruling out tubal
occlusion, and it is less invasive and
makes more efficient use of resources
than laparoscopy.
(Grade B).
Assessment of tubal factor
 Where appropriate expertise is available,
screening for tubal occlusion using
hysterosalpingo-contrast-ultrasonography
should be considered because it is an
effective alternative to HSG for women
who are not known to have co-morbidities
(Grade A)
Assessment of tubal factor
Women who are thought to
have co-morbidities should be
offered laparoscopy and dye so
that tubal and other pelvic
pathology can be assessed at
the same time. (Grade B)
4-Assessing uterine abnormalities
 Women should not be offered
hysteroscopy on its own as part of the
initial investigation unless clinically
indicated, because the effectiveness of
surgical treatment of uterine abnormalities
on improving pregnancy rates has not
been established. (Grade B)
Unnecessary laparoscopy!!!
 It is not cost effective to do
diagnostic laparoscopy as part of
the initial infertility evaluation
when:
History, and physical examination,
TVS, HSG, and Midluteal progesterone
are all normal (Grade B)
Basic infertility inves,Prof.S.Roshdy
When To Do Laparoscopy For tubal
evaluation?
 When associated pelvic co
morbidities (PID, previous Ectopic,
endometriosis ..etc) :evaluation of
the pelvis is required.
(Grade B)
Hysteroscopy has NO
role in routine
evaluation
of infertility
Basic infertility inves,Prof.S.Roshdy
Indications of Hysteroscopy as workup of
infertility?
 Abnormal HSG
 When Laparoscopy is indicated as in
Unexplained infertility ?
 Before IVF in cases of
unexplained infertility ?!!!!
 After Failed IVF ?
No Role for...
1. Postcoital test.
2. Endometrial biopsy
3. Antisperm antibodies
4. Routine cervical cultures
5. Thyroid function ( in absence of symptoms
suggestive of of thyroid disease)
6.Prolactin (in absence of galactorrhoea and
…)
The basic infertility evaluation of
all couples consists of:
 Semen analysis
 Assessment of ovulatory function
 Determination of tubal patency and presence or absence
of abnormalities of the uterine cavity,usually by HSG.
 Diagnostic laparoscopy is indicated for women with
suspected endometriosis or pelvic adhesions.
 Ovarian reserve is assessed with day 3 (FSH) and
estradiol levels in women over 35 years of age and in
younger women with risk factors for premature ovarian
failure.
Basic infertility inves,Prof.S.Roshdy

Contenu connexe

Tendances

Current Management of Anovulatory Infertility
Current Management of Anovulatory InfertilityCurrent Management of Anovulatory Infertility
Current Management of Anovulatory InfertilityWale Jesudemi
 
Ovulation induction
Ovulation inductionOvulation induction
Ovulation inductionnermine amin
 
Optimal protocols for Ovulation induction (Assisted Reproductive technologies)
Optimal protocols for Ovulation induction (Assisted Reproductive technologies)Optimal protocols for Ovulation induction (Assisted Reproductive technologies)
Optimal protocols for Ovulation induction (Assisted Reproductive technologies)Anu Test Tube Baby Centre
 
OVARIAN RESERVE DIAGNOSIS & MANAGEMENT DR Sharda Jain
OVARIAN RESERVE DIAGNOSIS & MANAGEMENT DR Sharda Jain OVARIAN RESERVE DIAGNOSIS & MANAGEMENT DR Sharda Jain
OVARIAN RESERVE DIAGNOSIS & MANAGEMENT DR Sharda Jain Lifecare Centre
 
EVIDENCE BASED PRACTICAL TIPS FOR LUTEAL PHASE SUPPORT BY DR SHASHWAT JANI
EVIDENCE BASED PRACTICAL TIPS FOR LUTEAL PHASE SUPPORT BY DR SHASHWAT JANIEVIDENCE BASED PRACTICAL TIPS FOR LUTEAL PHASE SUPPORT BY DR SHASHWAT JANI
EVIDENCE BASED PRACTICAL TIPS FOR LUTEAL PHASE SUPPORT BY DR SHASHWAT JANIDR SHASHWAT JANI
 
Ovulation induction in IUI
Ovulation induction in IUIOvulation induction in IUI
Ovulation induction in IUIPoonam Loomba
 
NICE Guidelines 2013, in relation to IUI & IVF Dr. Jyoti Agarwal,Dr. Sharda J...
NICE Guidelines 2013, in relation to IUI & IVF Dr. Jyoti Agarwal,Dr. Sharda J...NICE Guidelines 2013, in relation to IUI & IVF Dr. Jyoti Agarwal,Dr. Sharda J...
NICE Guidelines 2013, in relation to IUI & IVF Dr. Jyoti Agarwal,Dr. Sharda J...Lifecare Centre
 
Prediction and prevention of Preeclampsia
Prediction and prevention of PreeclampsiaPrediction and prevention of Preeclampsia
Prediction and prevention of PreeclampsiaNiranjan Chavan
 
Unexplained Infertility - By Dr Dhorepatil Bharati
Unexplained Infertility - By Dr Dhorepatil BharatiUnexplained Infertility - By Dr Dhorepatil Bharati
Unexplained Infertility - By Dr Dhorepatil BharatiBharati Dhorepatil
 
ENDOMETRIAL PREPARATION IN FROZEN EMBRYO TRANSFER CYCLES
ENDOMETRIAL PREPARATION IN FROZEN EMBRYO TRANSFER CYCLESENDOMETRIAL PREPARATION IN FROZEN EMBRYO TRANSFER CYCLES
ENDOMETRIAL PREPARATION IN FROZEN EMBRYO TRANSFER CYCLESAboubakr Elnashar
 
Gonadotrpin ovarian stimulation
Gonadotrpin ovarian stimulationGonadotrpin ovarian stimulation
Gonadotrpin ovarian stimulationAboubakr Elnashar
 
Luteal Phase Insufficiency.pptx
Luteal Phase Insufficiency.pptxLuteal Phase Insufficiency.pptx
Luteal Phase Insufficiency.pptxRaju Nair
 
GnRH Antagonists in Controlled Ovarian Stimulation
GnRH Antagonists in Controlled Ovarian StimulationGnRH Antagonists in Controlled Ovarian Stimulation
GnRH Antagonists in Controlled Ovarian StimulationSandro Esteves
 
Ovarian reserve o warda
Ovarian reserve  o wardaOvarian reserve  o warda
Ovarian reserve o wardaOsama Warda
 
AZOOSPERMIA Management Made Simple : “Stepwise approach”
AZOOSPERMIAManagement  Made  Simple : “Stepwise approach” AZOOSPERMIAManagement  Made  Simple : “Stepwise approach”
AZOOSPERMIA Management Made Simple : “Stepwise approach” Lifecare Centre
 

Tendances (20)

Current Management of Anovulatory Infertility
Current Management of Anovulatory InfertilityCurrent Management of Anovulatory Infertility
Current Management of Anovulatory Infertility
 
Ovulation induction
Ovulation inductionOvulation induction
Ovulation induction
 
Optimal protocols for Ovulation induction (Assisted Reproductive technologies)
Optimal protocols for Ovulation induction (Assisted Reproductive technologies)Optimal protocols for Ovulation induction (Assisted Reproductive technologies)
Optimal protocols for Ovulation induction (Assisted Reproductive technologies)
 
OVARIAN RESERVE DIAGNOSIS & MANAGEMENT DR Sharda Jain
OVARIAN RESERVE DIAGNOSIS & MANAGEMENT DR Sharda Jain OVARIAN RESERVE DIAGNOSIS & MANAGEMENT DR Sharda Jain
OVARIAN RESERVE DIAGNOSIS & MANAGEMENT DR Sharda Jain
 
Intra uterine insemination for unexplained infertility
Intra uterine insemination for unexplained infertilityIntra uterine insemination for unexplained infertility
Intra uterine insemination for unexplained infertility
 
EVIDENCE BASED PRACTICAL TIPS FOR LUTEAL PHASE SUPPORT BY DR SHASHWAT JANI
EVIDENCE BASED PRACTICAL TIPS FOR LUTEAL PHASE SUPPORT BY DR SHASHWAT JANIEVIDENCE BASED PRACTICAL TIPS FOR LUTEAL PHASE SUPPORT BY DR SHASHWAT JANI
EVIDENCE BASED PRACTICAL TIPS FOR LUTEAL PHASE SUPPORT BY DR SHASHWAT JANI
 
Ovulation induction in IUI
Ovulation induction in IUIOvulation induction in IUI
Ovulation induction in IUI
 
Ovarian Factor Infertility
Ovarian Factor InfertilityOvarian Factor Infertility
Ovarian Factor Infertility
 
NICE Guidelines 2013, in relation to IUI & IVF Dr. Jyoti Agarwal,Dr. Sharda J...
NICE Guidelines 2013, in relation to IUI & IVF Dr. Jyoti Agarwal,Dr. Sharda J...NICE Guidelines 2013, in relation to IUI & IVF Dr. Jyoti Agarwal,Dr. Sharda J...
NICE Guidelines 2013, in relation to IUI & IVF Dr. Jyoti Agarwal,Dr. Sharda J...
 
Prediction and prevention of Preeclampsia
Prediction and prevention of PreeclampsiaPrediction and prevention of Preeclampsia
Prediction and prevention of Preeclampsia
 
Unexplained Infertility - By Dr Dhorepatil Bharati
Unexplained Infertility - By Dr Dhorepatil BharatiUnexplained Infertility - By Dr Dhorepatil Bharati
Unexplained Infertility - By Dr Dhorepatil Bharati
 
Ovarian stimulation
Ovarian stimulationOvarian stimulation
Ovarian stimulation
 
ENDOMETRIAL PREPARATION IN FROZEN EMBRYO TRANSFER CYCLES
ENDOMETRIAL PREPARATION IN FROZEN EMBRYO TRANSFER CYCLESENDOMETRIAL PREPARATION IN FROZEN EMBRYO TRANSFER CYCLES
ENDOMETRIAL PREPARATION IN FROZEN EMBRYO TRANSFER CYCLES
 
Gonadotrpin ovarian stimulation
Gonadotrpin ovarian stimulationGonadotrpin ovarian stimulation
Gonadotrpin ovarian stimulation
 
OVARIAN RESERVE
OVARIAN RESERVEOVARIAN RESERVE
OVARIAN RESERVE
 
Luteal Phase Insufficiency.pptx
Luteal Phase Insufficiency.pptxLuteal Phase Insufficiency.pptx
Luteal Phase Insufficiency.pptx
 
Induction of ovulation
Induction of ovulationInduction of ovulation
Induction of ovulation
 
GnRH Antagonists in Controlled Ovarian Stimulation
GnRH Antagonists in Controlled Ovarian StimulationGnRH Antagonists in Controlled Ovarian Stimulation
GnRH Antagonists in Controlled Ovarian Stimulation
 
Ovarian reserve o warda
Ovarian reserve  o wardaOvarian reserve  o warda
Ovarian reserve o warda
 
AZOOSPERMIA Management Made Simple : “Stepwise approach”
AZOOSPERMIAManagement  Made  Simple : “Stepwise approach” AZOOSPERMIAManagement  Made  Simple : “Stepwise approach”
AZOOSPERMIA Management Made Simple : “Stepwise approach”
 

Similaire à Basic infertility inves,Prof.S.Roshdy

How at assess an infertile couple
How at assess an infertile coupleHow at assess an infertile couple
How at assess an infertile coupleazza mokhtar
 
Subfertility / OBS & GYN ( updated )
Subfertility  / OBS & GYN ( updated  )Subfertility  / OBS & GYN ( updated  )
Subfertility / OBS & GYN ( updated )Diaa Srahin
 
Male and Female Subfertility
Male and Female SubfertilityMale and Female Subfertility
Male and Female SubfertilityDiaa Srahin
 
Female infertility and its causes
Female infertility and its causesFemale infertility and its causes
Female infertility and its causesLaveinyaBalaji1
 
Female infertility,Prof.Salah Roshdy
Female infertility,Prof.Salah RoshdyFemale infertility,Prof.Salah Roshdy
Female infertility,Prof.Salah RoshdySalah Roshdy AHMED
 
Infertility Seminar for 1st year Msc nursing
Infertility Seminar for 1st year Msc nursing Infertility Seminar for 1st year Msc nursing
Infertility Seminar for 1st year Msc nursing SrushtiGhadge
 
infertilityseminarppt-190718134710.pptx
infertilityseminarppt-190718134710.pptxinfertilityseminarppt-190718134710.pptx
infertilityseminarppt-190718134710.pptxSubi Babu
 
Clomiphene Citrate Stimulation Protocol for Non IVF Cycle
Clomiphene Citrate Stimulation Protocol for Non IVF CycleClomiphene Citrate Stimulation Protocol for Non IVF Cycle
Clomiphene Citrate Stimulation Protocol for Non IVF CycleDr.Laxmi Agrawal Shrikhande
 
Infertility Overview, Approach and Evaluation
Infertility Overview, Approach and EvaluationInfertility Overview, Approach and Evaluation
Infertility Overview, Approach and Evaluationedenfertilitycenters
 
Approach to Infertility By Essam Sidqi
Approach to Infertility By Essam SidqiApproach to Infertility By Essam Sidqi
Approach to Infertility By Essam SidqiEssam Sidqi Yaqoob
 
medical management of infertility,think before surgery!!!!
medical management of infertility,think before surgery!!!!medical management of infertility,think before surgery!!!!
medical management of infertility,think before surgery!!!!ShitalSavaliya1
 

Similaire à Basic infertility inves,Prof.S.Roshdy (20)

Subfertility
SubfertilitySubfertility
Subfertility
 
Overview of Recurrent Pregnancy Loss
Overview of Recurrent Pregnancy LossOverview of Recurrent Pregnancy Loss
Overview of Recurrent Pregnancy Loss
 
How at assess an infertile couple
How at assess an infertile coupleHow at assess an infertile couple
How at assess an infertile couple
 
Female infertility
Female infertilityFemale infertility
Female infertility
 
Subfertility / OBS & GYN ( updated )
Subfertility  / OBS & GYN ( updated  )Subfertility  / OBS & GYN ( updated  )
Subfertility / OBS & GYN ( updated )
 
Bovine Infertility
Bovine InfertilityBovine Infertility
Bovine Infertility
 
Male and Female Subfertility
Male and Female SubfertilityMale and Female Subfertility
Male and Female Subfertility
 
Infertility
InfertilityInfertility
Infertility
 
Female infertility and its causes
Female infertility and its causesFemale infertility and its causes
Female infertility and its causes
 
Infertility
InfertilityInfertility
Infertility
 
Female infertility,Prof.Salah Roshdy
Female infertility,Prof.Salah RoshdyFemale infertility,Prof.Salah Roshdy
Female infertility,Prof.Salah Roshdy
 
Infertility Seminar for 1st year Msc nursing
Infertility Seminar for 1st year Msc nursing Infertility Seminar for 1st year Msc nursing
Infertility Seminar for 1st year Msc nursing
 
Final
FinalFinal
Final
 
infertility.pptx
infertility.pptxinfertility.pptx
infertility.pptx
 
infertilityseminarppt-190718134710.pptx
infertilityseminarppt-190718134710.pptxinfertilityseminarppt-190718134710.pptx
infertilityseminarppt-190718134710.pptx
 
Infertility
InfertilityInfertility
Infertility
 
Clomiphene Citrate Stimulation Protocol for Non IVF Cycle
Clomiphene Citrate Stimulation Protocol for Non IVF CycleClomiphene Citrate Stimulation Protocol for Non IVF Cycle
Clomiphene Citrate Stimulation Protocol for Non IVF Cycle
 
Infertility Overview, Approach and Evaluation
Infertility Overview, Approach and EvaluationInfertility Overview, Approach and Evaluation
Infertility Overview, Approach and Evaluation
 
Approach to Infertility By Essam Sidqi
Approach to Infertility By Essam SidqiApproach to Infertility By Essam Sidqi
Approach to Infertility By Essam Sidqi
 
medical management of infertility,think before surgery!!!!
medical management of infertility,think before surgery!!!!medical management of infertility,think before surgery!!!!
medical management of infertility,think before surgery!!!!
 

Plus de Salah Roshdy AHMED

New frontiers in endometriosis.Prof Salah.Roshdy
New frontiers in endometriosis.Prof Salah.RoshdyNew frontiers in endometriosis.Prof Salah.Roshdy
New frontiers in endometriosis.Prof Salah.RoshdySalah Roshdy AHMED
 
Recent guidline for management of HDP.Prof Salah Roshdy
Recent guidline for management of HDP.Prof Salah RoshdyRecent guidline for management of HDP.Prof Salah Roshdy
Recent guidline for management of HDP.Prof Salah RoshdySalah Roshdy AHMED
 
Madical treatment of ectopic pregnancy .Prof. Salah Roshdy
Madical treatment of ectopic  pregnancy .Prof. Salah RoshdyMadical treatment of ectopic  pregnancy .Prof. Salah Roshdy
Madical treatment of ectopic pregnancy .Prof. Salah RoshdySalah Roshdy AHMED
 
Organ transplantation.Prof S. Roshdy
Organ transplantation.Prof S. RoshdyOrgan transplantation.Prof S. Roshdy
Organ transplantation.Prof S. RoshdySalah Roshdy AHMED
 
Placenta accreta .Prof.S. Roshdy
Placenta accreta .Prof.S. RoshdyPlacenta accreta .Prof.S. Roshdy
Placenta accreta .Prof.S. RoshdySalah Roshdy AHMED
 
Kisspeptin,prof.Salah Roshdy modified
Kisspeptin,prof.Salah Roshdy modifiedKisspeptin,prof.Salah Roshdy modified
Kisspeptin,prof.Salah Roshdy modifiedSalah Roshdy AHMED
 
Placenta & Fetal membrane.Prof.Salah Roshdy
Placenta & Fetal membrane.Prof.Salah RoshdyPlacenta & Fetal membrane.Prof.Salah Roshdy
Placenta & Fetal membrane.Prof.Salah RoshdySalah Roshdy AHMED
 
Evidence Based Management of Endometrioma
Evidence Based Management of EndometriomaEvidence Based Management of Endometrioma
Evidence Based Management of EndometriomaSalah Roshdy AHMED
 
H1N1 & Pregnancy.Prof Salah Roshdy
H1N1 & Pregnancy.Prof Salah Roshdy  H1N1 & Pregnancy.Prof Salah Roshdy
H1N1 & Pregnancy.Prof Salah Roshdy Salah Roshdy AHMED
 
Methotrexate in ectopic pregnancy prof.salah roshdy
Methotrexate in ectopic pregnancy prof.salah roshdyMethotrexate in ectopic pregnancy prof.salah roshdy
Methotrexate in ectopic pregnancy prof.salah roshdySalah Roshdy AHMED
 
Puerperium normal & abnormal prof.salah roshdy
Puerperium normal & abnormal prof.salah roshdyPuerperium normal & abnormal prof.salah roshdy
Puerperium normal & abnormal prof.salah roshdySalah Roshdy AHMED
 
Amniotic fluid disorder prof.salah
Amniotic fluid disorder prof.salahAmniotic fluid disorder prof.salah
Amniotic fluid disorder prof.salahSalah Roshdy AHMED
 
Pelvic endometrioma.prof.salah
Pelvic endometrioma.prof.salahPelvic endometrioma.prof.salah
Pelvic endometrioma.prof.salahSalah Roshdy AHMED
 
Management of the critically ill obstetric patient.prof.salah
Management of the critically ill obstetric patient.prof.salahManagement of the critically ill obstetric patient.prof.salah
Management of the critically ill obstetric patient.prof.salahSalah Roshdy AHMED
 

Plus de Salah Roshdy AHMED (20)

New frontiers in endometriosis.Prof Salah.Roshdy
New frontiers in endometriosis.Prof Salah.RoshdyNew frontiers in endometriosis.Prof Salah.Roshdy
New frontiers in endometriosis.Prof Salah.Roshdy
 
Recent guidline for management of HDP.Prof Salah Roshdy
Recent guidline for management of HDP.Prof Salah RoshdyRecent guidline for management of HDP.Prof Salah Roshdy
Recent guidline for management of HDP.Prof Salah Roshdy
 
Madical treatment of ectopic pregnancy .Prof. Salah Roshdy
Madical treatment of ectopic  pregnancy .Prof. Salah RoshdyMadical treatment of ectopic  pregnancy .Prof. Salah Roshdy
Madical treatment of ectopic pregnancy .Prof. Salah Roshdy
 
Organ transplantation.Prof S. Roshdy
Organ transplantation.Prof S. RoshdyOrgan transplantation.Prof S. Roshdy
Organ transplantation.Prof S. Roshdy
 
Placenta accreta .Prof.S. Roshdy
Placenta accreta .Prof.S. RoshdyPlacenta accreta .Prof.S. Roshdy
Placenta accreta .Prof.S. Roshdy
 
Aub prof.Salah Roshdy@
Aub prof.Salah Roshdy@Aub prof.Salah Roshdy@
Aub prof.Salah Roshdy@
 
Kisspeptin,prof.Salah Roshdy modified
Kisspeptin,prof.Salah Roshdy modifiedKisspeptin,prof.Salah Roshdy modified
Kisspeptin,prof.Salah Roshdy modified
 
Placenta & Fetal membrane.Prof.Salah Roshdy
Placenta & Fetal membrane.Prof.Salah RoshdyPlacenta & Fetal membrane.Prof.Salah Roshdy
Placenta & Fetal membrane.Prof.Salah Roshdy
 
Evidence Based Management of Endometrioma
Evidence Based Management of EndometriomaEvidence Based Management of Endometrioma
Evidence Based Management of Endometrioma
 
AUB.Prof.Salah Roshdy
AUB.Prof.Salah RoshdyAUB.Prof.Salah Roshdy
AUB.Prof.Salah Roshdy
 
H1N1 & Pregnancy.Prof Salah Roshdy
H1N1 & Pregnancy.Prof Salah Roshdy  H1N1 & Pregnancy.Prof Salah Roshdy
H1N1 & Pregnancy.Prof Salah Roshdy
 
Benign ovarian tumors
Benign ovarian tumorsBenign ovarian tumors
Benign ovarian tumors
 
Methotrexate in ectopic pregnancy prof.salah roshdy
Methotrexate in ectopic pregnancy prof.salah roshdyMethotrexate in ectopic pregnancy prof.salah roshdy
Methotrexate in ectopic pregnancy prof.salah roshdy
 
Puerperium normal & abnormal prof.salah roshdy
Puerperium normal & abnormal prof.salah roshdyPuerperium normal & abnormal prof.salah roshdy
Puerperium normal & abnormal prof.salah roshdy
 
Stillbirth prof.salah roshdy
Stillbirth prof.salah roshdyStillbirth prof.salah roshdy
Stillbirth prof.salah roshdy
 
Amniotic fluid disorder prof.salah
Amniotic fluid disorder prof.salahAmniotic fluid disorder prof.salah
Amniotic fluid disorder prof.salah
 
Atypical pet prof.salah 1
Atypical pet prof.salah 1Atypical pet prof.salah 1
Atypical pet prof.salah 1
 
Multiple pregnancy.prof.salah
Multiple pregnancy.prof.salahMultiple pregnancy.prof.salah
Multiple pregnancy.prof.salah
 
Pelvic endometrioma.prof.salah
Pelvic endometrioma.prof.salahPelvic endometrioma.prof.salah
Pelvic endometrioma.prof.salah
 
Management of the critically ill obstetric patient.prof.salah
Management of the critically ill obstetric patient.prof.salahManagement of the critically ill obstetric patient.prof.salah
Management of the critically ill obstetric patient.prof.salah
 

Dernier

SGK NGẠT NƯỚC ĐHYHN RẤT LÀ HAY NHA .pdf
SGK NGẠT NƯỚC ĐHYHN RẤT LÀ HAY NHA    .pdfSGK NGẠT NƯỚC ĐHYHN RẤT LÀ HAY NHA    .pdf
SGK NGẠT NƯỚC ĐHYHN RẤT LÀ HAY NHA .pdfHongBiThi1
 
pA2 value, Schild plot and pD2 values- applications in pharmacology
pA2 value, Schild plot and pD2 values- applications in pharmacologypA2 value, Schild plot and pD2 values- applications in pharmacology
pA2 value, Schild plot and pD2 values- applications in pharmacologyDeepakDaniel9
 
EXERCISE PERFORMANCE.pptx, Lung function
EXERCISE PERFORMANCE.pptx, Lung functionEXERCISE PERFORMANCE.pptx, Lung function
EXERCISE PERFORMANCE.pptx, Lung functionkrishnareddy157915
 
ayurvedic formulations herbal drug technologyppt
ayurvedic formulations herbal drug technologypptayurvedic formulations herbal drug technologyppt
ayurvedic formulations herbal drug technologypptPradnya Wadekar
 
Trustworthiness of AI based predictions Aachen 2024
Trustworthiness of AI based predictions Aachen 2024Trustworthiness of AI based predictions Aachen 2024
Trustworthiness of AI based predictions Aachen 2024EwoutSteyerberg1
 
Neurological history taking (2024) .
Neurological  history  taking  (2024)  .Neurological  history  taking  (2024)  .
Neurological history taking (2024) .Mohamed Rizk Khodair
 
"Radical excision of DIE in subferile women with deep infiltrating endometrio...
"Radical excision of DIE in subferile women with deep infiltrating endometrio..."Radical excision of DIE in subferile women with deep infiltrating endometrio...
"Radical excision of DIE in subferile women with deep infiltrating endometrio...Sujoy Dasgupta
 
Role of Soap based and synthetic or syndets bar
Role of  Soap based and synthetic or syndets barRole of  Soap based and synthetic or syndets bar
Role of Soap based and synthetic or syndets barmohitRahangdale
 
AORTIC DISSECTION and management of aortic dissection
AORTIC DISSECTION and management of aortic dissectionAORTIC DISSECTION and management of aortic dissection
AORTIC DISSECTION and management of aortic dissectiondrhanifmohdali
 
Different drug regularity bodies in different countries.
Different drug regularity bodies in different countries.Different drug regularity bodies in different countries.
Different drug regularity bodies in different countries.kishan singh tomar
 
power point presentation of Clinical evaluation of strabismus
power point presentation of Clinical evaluation  of strabismuspower point presentation of Clinical evaluation  of strabismus
power point presentation of Clinical evaluation of strabismusChandrasekar Reddy
 
SGK LEUKEMIA KINH DÒNG BẠCH CÂU HẠT HAY.pdf
SGK LEUKEMIA KINH DÒNG BẠCH CÂU HẠT HAY.pdfSGK LEUKEMIA KINH DÒNG BẠCH CÂU HẠT HAY.pdf
SGK LEUKEMIA KINH DÒNG BẠCH CÂU HẠT HAY.pdfHongBiThi1
 
Female Reproductive Physiology Before Pregnancy
Female Reproductive Physiology Before PregnancyFemale Reproductive Physiology Before Pregnancy
Female Reproductive Physiology Before PregnancyMedicoseAcademics
 
BENIGN BREAST DISEASE
BENIGN BREAST DISEASE BENIGN BREAST DISEASE
BENIGN BREAST DISEASE Mamatha Lakka
 
Clinical Research Informatics Year-in-Review 2024
Clinical Research Informatics Year-in-Review 2024Clinical Research Informatics Year-in-Review 2024
Clinical Research Informatics Year-in-Review 2024Peter Embi
 
Physiology of Smooth Muscles -Mechanics of contraction and relaxation
Physiology of Smooth Muscles -Mechanics of contraction and relaxationPhysiology of Smooth Muscles -Mechanics of contraction and relaxation
Physiology of Smooth Muscles -Mechanics of contraction and relaxationMedicoseAcademics
 
Bulimia nervosa ( Eating Disorders) Mental Health Nursing.
Bulimia nervosa ( Eating Disorders) Mental Health Nursing.Bulimia nervosa ( Eating Disorders) Mental Health Nursing.
Bulimia nervosa ( Eating Disorders) Mental Health Nursing.aarjukhadka22
 
SGK RỐI LOẠN TOAN KIỀM ĐHYHN RẤT HAY VÀ ĐẶC SẮC.pdf
SGK RỐI LOẠN TOAN KIỀM ĐHYHN RẤT HAY VÀ ĐẶC SẮC.pdfSGK RỐI LOẠN TOAN KIỀM ĐHYHN RẤT HAY VÀ ĐẶC SẮC.pdf
SGK RỐI LOẠN TOAN KIỀM ĐHYHN RẤT HAY VÀ ĐẶC SẮC.pdfHongBiThi1
 
Mental health Team. Dr Senthil Thirusangu
Mental health Team. Dr Senthil ThirusanguMental health Team. Dr Senthil Thirusangu
Mental health Team. Dr Senthil Thirusangu Medical University
 

Dernier (20)

SGK NGẠT NƯỚC ĐHYHN RẤT LÀ HAY NHA .pdf
SGK NGẠT NƯỚC ĐHYHN RẤT LÀ HAY NHA    .pdfSGK NGẠT NƯỚC ĐHYHN RẤT LÀ HAY NHA    .pdf
SGK NGẠT NƯỚC ĐHYHN RẤT LÀ HAY NHA .pdf
 
pA2 value, Schild plot and pD2 values- applications in pharmacology
pA2 value, Schild plot and pD2 values- applications in pharmacologypA2 value, Schild plot and pD2 values- applications in pharmacology
pA2 value, Schild plot and pD2 values- applications in pharmacology
 
EXERCISE PERFORMANCE.pptx, Lung function
EXERCISE PERFORMANCE.pptx, Lung functionEXERCISE PERFORMANCE.pptx, Lung function
EXERCISE PERFORMANCE.pptx, Lung function
 
ayurvedic formulations herbal drug technologyppt
ayurvedic formulations herbal drug technologypptayurvedic formulations herbal drug technologyppt
ayurvedic formulations herbal drug technologyppt
 
GOUT UPDATE AHMED YEHIA 2024, case based approach with application of the lat...
GOUT UPDATE AHMED YEHIA 2024, case based approach with application of the lat...GOUT UPDATE AHMED YEHIA 2024, case based approach with application of the lat...
GOUT UPDATE AHMED YEHIA 2024, case based approach with application of the lat...
 
Trustworthiness of AI based predictions Aachen 2024
Trustworthiness of AI based predictions Aachen 2024Trustworthiness of AI based predictions Aachen 2024
Trustworthiness of AI based predictions Aachen 2024
 
Neurological history taking (2024) .
Neurological  history  taking  (2024)  .Neurological  history  taking  (2024)  .
Neurological history taking (2024) .
 
"Radical excision of DIE in subferile women with deep infiltrating endometrio...
"Radical excision of DIE in subferile women with deep infiltrating endometrio..."Radical excision of DIE in subferile women with deep infiltrating endometrio...
"Radical excision of DIE in subferile women with deep infiltrating endometrio...
 
Role of Soap based and synthetic or syndets bar
Role of  Soap based and synthetic or syndets barRole of  Soap based and synthetic or syndets bar
Role of Soap based and synthetic or syndets bar
 
AORTIC DISSECTION and management of aortic dissection
AORTIC DISSECTION and management of aortic dissectionAORTIC DISSECTION and management of aortic dissection
AORTIC DISSECTION and management of aortic dissection
 
Different drug regularity bodies in different countries.
Different drug regularity bodies in different countries.Different drug regularity bodies in different countries.
Different drug regularity bodies in different countries.
 
power point presentation of Clinical evaluation of strabismus
power point presentation of Clinical evaluation  of strabismuspower point presentation of Clinical evaluation  of strabismus
power point presentation of Clinical evaluation of strabismus
 
SGK LEUKEMIA KINH DÒNG BẠCH CÂU HẠT HAY.pdf
SGK LEUKEMIA KINH DÒNG BẠCH CÂU HẠT HAY.pdfSGK LEUKEMIA KINH DÒNG BẠCH CÂU HẠT HAY.pdf
SGK LEUKEMIA KINH DÒNG BẠCH CÂU HẠT HAY.pdf
 
Female Reproductive Physiology Before Pregnancy
Female Reproductive Physiology Before PregnancyFemale Reproductive Physiology Before Pregnancy
Female Reproductive Physiology Before Pregnancy
 
BENIGN BREAST DISEASE
BENIGN BREAST DISEASE BENIGN BREAST DISEASE
BENIGN BREAST DISEASE
 
Clinical Research Informatics Year-in-Review 2024
Clinical Research Informatics Year-in-Review 2024Clinical Research Informatics Year-in-Review 2024
Clinical Research Informatics Year-in-Review 2024
 
Physiology of Smooth Muscles -Mechanics of contraction and relaxation
Physiology of Smooth Muscles -Mechanics of contraction and relaxationPhysiology of Smooth Muscles -Mechanics of contraction and relaxation
Physiology of Smooth Muscles -Mechanics of contraction and relaxation
 
Bulimia nervosa ( Eating Disorders) Mental Health Nursing.
Bulimia nervosa ( Eating Disorders) Mental Health Nursing.Bulimia nervosa ( Eating Disorders) Mental Health Nursing.
Bulimia nervosa ( Eating Disorders) Mental Health Nursing.
 
SGK RỐI LOẠN TOAN KIỀM ĐHYHN RẤT HAY VÀ ĐẶC SẮC.pdf
SGK RỐI LOẠN TOAN KIỀM ĐHYHN RẤT HAY VÀ ĐẶC SẮC.pdfSGK RỐI LOẠN TOAN KIỀM ĐHYHN RẤT HAY VÀ ĐẶC SẮC.pdf
SGK RỐI LOẠN TOAN KIỀM ĐHYHN RẤT HAY VÀ ĐẶC SẮC.pdf
 
Mental health Team. Dr Senthil Thirusangu
Mental health Team. Dr Senthil ThirusanguMental health Team. Dr Senthil Thirusangu
Mental health Team. Dr Senthil Thirusangu
 

Basic infertility inves,Prof.S.Roshdy

  • 1. Basic Infertility Investigation Prof.Salah Roshdy,MD Prof. of Obstetrics & Gynecology Sohag University 2018
  • 2. Objectives  know definitions of primary and secondary infertility  • understand the causes of infertility  • know the initial investigations of the infertile couple  Investigate male factor  • Test for ovulation  • Test for tubal patency  • Investigation role of laparoscopy and hysteroscopy
  • 3. INTRODUCTION  Infertility is a common condition with important psychologic, economic, demographic, and medical implications.  Infertility is a unique medical condition because it involves a couple, rather than a single individual.
  • 4. DEFINITIONS  It is defined as inability of a couple to conceive after 12 months of regular intercourse without use of contraception in women less than 35 years of age; and  after six months in women 35 years and older.  Some clinicians use the term subfertility to describe this failure to conceive unless the couple has been proven to be sterile.
  • 5. Primary infertility is the term used to describe a couple that has never been able to conceive ,after at least 1 year of unprotected intercourse.
  • 6. Secondary infertility Secondary infertility describes couples who have previously been pregnant at least once, but have not been able to achieve another pregnancy.
  • 7. NORMAL FERTILITY  A study examined the number of months to conception in 5574 normal women who had unprotected intercourse and who became pregnant . Eighty-five percent of the women conceived within 12 months.  Five to 15 percent of apparently normal couples will conceive in the second 12 months of attempted conception so that after 24 months , 95 percent of couples will have conceived.
  • 8. Natural Cumulative Pregnancy Rate 1 2 3 4 5 6 7 8 9 10 11 12 24 0 10 20 30 40 50 60 70 80 90 1 2 3 4 5 6 7 8 9 10 11 12 24 % pregnant/month Months of trying
  • 9. PREVALENCE Of INFERTILITY ranges from 12 to 18 %. women 15 to 34 years (7.3 to 9.1 percent)  35 to 39 years (25 percent) 40 to 44 years (30 percent).
  • 11.  The World Health Organization (WHO) task force on Diagnosis and Treatment of Infertility performed a study of 8500 infertile couples and utilized standard diagnostic criteria to determine the medical conditions contributing to infertility.  female factor : 38 %  Male factor : 20%  Both : 27%  UI : 15%
  • 12. Male factor  1-Endocrine and systemic disorders (hypogonadotropic hypogonadism)2-5%  A-Congenital disorders  B- Acquired disorders  C-Systemic disorders:
  • 13. 2-Primary testicular defects in spermatogenesis(65 to 80 %)  A-Congenital disorders;  B-Acquired disorders  C-Systemic illness  D-Genetic causes of dysspermatogenesis  3-Sperm transport disorders(5%)  4-Sexual dysfunction:  5-Idiopathic male infertility(10-20%)
  • 15. 1-OVARY  Ovulatory disorders: Infrequent ovulation (oligoovulation) or absent ovulation (anovulation). Oocyte aging:  Ovarian cysts:
  • 16. An Anovulation Hypothalamic Pituitary Ovarian Physiologic • Adolescence • Perimenopause • Lactation • Pregnancy Hyperandrogenic • PCOS • CAH • Androgen tumors Hypothalamic Dysfunction • Primary hypothalamic • Anorexia Nervosa • Extreme exercise • Hyperprolactinemia • Thyroid disease • Primary pituitary disease • Medications • Premature ovarian failure • Iatrogenic (chemo/rad) Hyperinsulinemic • PCOS • DM/Pre-diabetes • Metabolic syndrome • Obesity Endometrial
  • 17. W H O classification of anovulation LHRH FSHLH Hypothalamo- pituitary WHO Type 1: Hypogonadotropic hypogonadal anovulation (hypothalamic amenorrhea): Anovulation WHO Type 2: Normogonadotropic normoestrogenic anovulation Ovarian failure WHO Type 3: Hypergonadotropic hypoestrogenic anovulation:
  • 18. The Clues Hot flushes Irregular/absent periods Short cycle Amenorrhoea Weight loss/Exercise/Stress Drug-induced Other disease LHRH FSHLH Irregular menses Weight gain PCOS signs/symptoms
  • 19.  NIH Criteria 1990:  Menstrual irregularity due to anovulation or oligo-ovulation  Evidence of clinical or biochemical hyperandrogenism  Hirsutism, acne, male pattern baldness  High serum androgen levels  Exclusion of other causes (CAH, tumors, hyperprolactinemia) PCOS
  • 20.  Rotterdam Criteria (2 out of 3)2003:  Menstrual irregularity due to anovulation oligo-ovulation  Evidence of clinical or biochemical hyperandrogenism  Polycystic ovaries by US  presence of 12 or more follicles in each ovary measuring 2 to 9 mm in diameter and/or increased ovarian volume. * In addition, other etiologies (congenital adrenal hyperplasias, androgen-secreting tumors, Cushing's syndrome) must be excluded.
  • 21.  AES criteria 2006: Presence of three features  Androgen excess (clinical and/or biochemical hyperandrogenism)  Ovarian dysfunction (oligo-anovulation and/or polycystic ovarian morphology)  Exclusion of other androgen excess or ovulatory disorders
  • 24. 2-FALLOPIAN TUBE ABNORMALITIES/PELVIC ADHESIONS  Tubal disease and pelvic adhesions prevent normal transport of the oocyte and sperm through the fallopian tube.  PID  Severe endometriosis  Previous surgery or non-tubal infection (eg, appendicitis, inflammatory bowel disease),  Pelvic TB
  • 25. Hydrosalpinx:  Women with distal tubal obstruction may develop hydrosalpinges, which decrease the success rate of (IVF). In addition to obstruction to sperm migration, hydrosalpinges appear to reduce fertility by  retrograde flow of tubal contents into the endometrial cavity, which creates a hostile environment to implantation of an embryo.
  • 26. Hydrosalpinx:  Treatment of hydrosalpinx before IVF Negative effect on PR, IR, early pregnancy loss & LBR. LBR are reduced by 50%  WHY?  The fluid of hydrosalpinx:  1.Mechanical barrier to implantation: embryo to float  2.Deficient to support the developing embryo  3.Toxic to the developing embryo
  • 27. Hydrosalpinx:  There is good evidence for recommending :  laparoscopic salpingectomy or  proximal tubal occlusion
  • 28. Classification of Tubal disease  British Fertility Society  Minor  Proximal occlusion without tubal fibrosis  Distal occlusion without tubal distension  Healthy mucosal appearance at HSG, salpingoscopy  Flimsy peritubal/ovarian adhesions.
  • 29.  Intermediate  Unilateral severe tubal damage  Limited dense adhesions of tubes & ovaries  Severe  Bilateral severe tubal damage  Extensive tubal fibrosis  Tubal distension >1.5 cm  Abnormal mucosal appearance  Bipolar occlusion  Extensive dense adhesion
  • 30. 3-UTERUS  Impaired implantation, either mechanical or due to reduced endometrial receptivity, are the basis of uterine causes of infertility  Uterine leiomyomata:A meta-analysis showed  that only leiomyomata with a submucosal or intracavitary component were associated with lower pregnancy and implantation rates.  The likely mechanism is inhibition to normal implantation.
  • 31.  Uterine anomalies; Uterine abnormalities are thought to cause infertility by interfering with normal implantation. Müllerian anomalies are a significant cause of (RPL), with the septate uterus associated with the poorest reproductive outcome .  Other structural abnormalities associated with infertility include endometrial polyps, and synechiae from prior pregnancyrelated curettage.
  • 32. ENDOMETRIOSIS Mechanisms which decrease fertility in women with endometriosis include  Anatomic distortion from pelvic adhesions, damage to ovarian tissue by endometrioma formation and surgical resection,  and the production of substances such as cytokines and growth factors which impair the normal processes of ovulation, fertilization, and implantation.
  • 33. 4-CERVICAL FACTORS  Normal midcycle cervical mucus facilitates the transport of sperm.  Congenital malformations and trauma to the cervix (including surgery) may result in stenosis and inability of the cervix to produce normal mucus, thereby impairing fertility.
  • 34. 5-UNEXPLAINED  Unexplained infertility is the diagnosis given to couples after a thorough evaluation has not revealed a cause.  Many cases of unexplained infertility may be due to small contributions from multiple factors.
  • 35. When To start Workup ( investigations)?  An infertility evaluation is usually initiated after one year of regular unprotected intercourse in women under age 35 years and after six months of unprotected intercourse in women age 35 years and older.  However, the evaluation may be initiated sooner in women with  irregular menstrual cycles or endometriosis,  a history of PID,  or reproductive tract malformations.
  • 36. The Most Important Factor in the Evaluation of the Infertile Couple Is: History
  • 37. From: The diagnosis of male infertility: an analysis of the evidence to support the development of global WHO guidance— challenges and future research opportunities Hum Reprod Update. 2017;23(6):660-680. doi:10.1093/humupd/dmx021 Hum Reprod Update | © The Author 2017. Published by Oxford University Press on behalf of the European Society of Human Reproduction and Embryology.This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the
  • 38. History-General  Both couples should be present  Age  Previous pregnancies by each partner  Duration of infertility  Sexual history  Frequency and timing of intercourse  Use of lubricants  Impotence, dyspareunia  Contraceptive history
  • 39. History-Female  Previous female pelvic surgery  PID  Appendicitis  IUD use  Ectopic pregnancy history  Endometriosis  Leiomyoma
  • 40. History-Female  Irregular menses, amenorrhea, detailed menstrual history  Molimina  Vasomotor symptoms  Changes of hair growth.breast discharge  Stress  Weight changes  Exercise-drug –radiation -chemotherapy  Cervical and uterine surgery
  • 41. Physical Exam-Female  Thyroid exam  BMI  Hair distribution  Galactorrhea  Scar in the abdomen  Pelvic masses  Uterosacral nodularity  Abdominopelvic tenderness  Uterine enlargement  Uterine mobility  Cervical abnormalities  Abnormal vaginal discharge
  • 42.  Very long list of tests, have been advocated to assist in determining the cause of the infertility in the diagnostic evaluation of infertile couple.  The necessity and cost effectiveness of performing many of these tests and correcting the abnormalities found by them have not been demonstrated.
  • 43. 1-Investigations of Male Factor  Conventional semen analysis  Computer- assisted sperm analysis (CASA)  A variety of sperm function tests - The acrosome reaction test - Hypo-osmotic swelling test - Measurement of generation of Reactive oxygen species - Sperm capacitation assays - Hemizona-binding assay - Hamster penetration test - Human sperm-zona penetration assay  A variety of imaging techniques for detection of varicocele
  • 44. Semen Analysis  Semen analysis is the key laboratory assessment of the male partner of an infertile couple.  The standard semen analysis consists of the following:  Semen volume and pH  ● Microscopy for • Sperm concentration, count, motility, and morphology • Debris and agglutination • Leukocyte count• Immature germ cells
  • 45. Semen Analysis  The semen sample should be collected after two to seven days ejaculatory abstinence.  If possible, the patient should collect the sample by masturbation at the doctor's office. If not possible, then the sample may be  collected at home and delivered to the laboratory within an hour of collection.
  • 48. 2-Assessment of ovulation  Basal body temperature  Urine LH kits  Mid luteal serum progesterone  Routine hormonal profile: FSH, LH, Prolactin,TSH  Endometrial biopsy  Serial pelvic Ultrasonography.  A variety of tests for assessment of ovarian reserve such as D3 FSH & E2, Inhibin B, Clomid challenge test, TVS for ovarian volume, antral follicle count and Stromal blood flow.
  • 49. Evidence of ovulation:  1. Menstrual history of regular cycles.  2. Serum progesterone in the mid-luteal phase of their cycle (day 21 of a 28-day cycle) even if they have regular menstrual cycles.  3. Serum gonadotrophins ( FSH & LH) on Day2-3 especially in irregular periods.  (N.B.: No role for basal body temperature charts)
  • 50. Further investigations  Ovarian reserve  -More important in >35 years old, suspected ovarian failure and to detect response to ovulation induction.  1. Total antral follicle count.  2. AMH of less than or equal to 5.4 pmol/l for a low response and greater than or equal to 25.0 pmol/l for a high response  3. FSH greater than 8.9 IU/l for a low response and less than 4 IU/l for a high response.
  • 51. D 3 FSH  Both the day 3 FSH level and the CCCT, which is a provocative test for measurement of FSH, are widely used for screening ovarian reserve.  The CCCT involves oral administration of 100 mg clomiphene citrate on cycle days 5 through 9 with measurement of day 3 and day 10 FSH levels and day 3 estradiol level.  A value less than 10 mIU/mL suggestive of adequate ovarian reserve.
  • 52. Antral follicle count (AFC)  Ultrasound examination can be used to determine the number of antral follicles (defined as follicles measuring 2 to 10 mm in diameter). On transvaginal ultrasound,  The ovaries are visualized in their transverse and longitudinal planes and the antral follicles are counted and measured; the size of the follicle is the mean of two perpendicular diameters, one of which should be the largest dimension of each follicle
  • 53. AFC  A low AFC ranging from <4 to 10 antral follicles between days two and four of a regular menstrual cycle suggests poor ovarian reserve.  Although AFC is a good predictor of ovarian reserve and response,  It is less predictive of oocyte quality,the ability to conceive with IVF, and pregnancy outcome.
  • 55. Antimüllerian hormone (AMH)  is expressed by the small (<8 mm) preantral and early antral follicles. The AMH level reflects the size of the primordial follicle pool, and may be the best biochemical marker of ovarian function across an array of clinical situations.  The AMH level appears to be an early, reliable, direct indicator of declining ovarian function.  AMH level correlates with the number of oocytes retrieved after stimulation, and is the best biomarker for predicting poor and excessive ovarian response.
  • 56. AMH  Unlike the day 3 FSH, AMH can be measured anytime during the menstrual cycle.  AMH <0.5 ng/mL predicts reduced ovarian reserve with less than three follicles in an IVF cycle  ● AMH <1.0 ng/mL predicts baseline ovarian reserve with a likelihood of limited eggs at retrieval.
  • 57. AMH  ● AMH >1.0 ng/mL but <3.5 ng/mL suggests a good response to stimulation  AMH >3.5 ng/mL predicts a vigorous response to ovarian stimulation and caution should be exercised in order to avoid ovarian hyperstimulation syndrome.
  • 59. No evidence for:  - ovarian volume  - ovarian blood flow  - inhibin B  -estradiol (E2)
  • 60. 3-Investigations of tubal factor  Hysterosalpingography (HSG)  Hysterosalpingo-contrast sonography (HyCoSy)  Laparoscopy with chromotubation  Hydrolaparoscopy.  Fluoroscopic/hysteroscopic- selective tubal cannulation.  Falloposcopy
  • 61. Assessment of the uterine cavity  Modalities to assess the uterine cavity include :  Saline Infusion Sono- hysterography (SIS)  Three dimensional sonography  Hysterosalpingography (HSG)  Hysteroscopy
  • 62. Laparoscopy as a diagnostic tool in infertility has diminished markedly  Today, we rarely perform diagnostic laparoscopy in infertile women. (Tulandi, 2017)  1.The benefit of diagnostic laparoscopy with no risk factors for intra-abdominal adhesions: small.  2.Treatment of stage I or II endometriosis: small increase in PR.  3.Alternative treatments of infertility are available  Superovulationwith IUI  IVF.
  • 63. Indications  1.Abnormal HSG or US  2.Young women with history or symptoms suggestive of pelvic disease. Even if HSG indicates patency in one or both tubes  .A history of PID,  .Ectopic pregnancy.  .Pelvic surgery.  .Chronic pelvic pain  . Current dysmenorrhea, pelvic pain, or deep dyspareunia; previous complicated appendicitis
  • 64. Indications  3. Three cycles of super ovulation with IUI are unsuccessful.  4. After failed IVF  -Laparoscopy after failed IVF:(Littman et al., 2005).  Pathology in 50%  endometriosis or adhesions  No RCTs have confirmed this rate.
  • 65. TESTS OF LIMITED CLINICAL UTILITY  PCT for assessment of the cervical factor.  Chlamydia trachomatis antibodies .  Endometrial biopsy  Basal body temperature records  Zonafree hamster oocyte penetration test  Mycoplasma cultures  Testing for antibodies; antiphospholipid, antisperm, antinuclear, and antithyroid antibodies.  Karyotype
  • 66. Controversies  Lack of agreement exists among trained infertility specialists with regard to prognostic utility as well as criteria of normality of many of these tests?  There is no consensus on which tests are essential before reaching the exact diagnosis ?
  • 67. Investigations of infertile couple Evidence Medicine Based Era National Evidence-Based Clinical Guidelines “Assessment and treatment for people with fertility problems developed by the National Collaborating Centre for Women and Children's Health on behalf of the National Institutefor Clinical Excellence (NICE)” February 2004
  • 68. Grading – Evidence Based Recommendations A recommendation I evidence B recommendation II evidence C recommendation III evidence D recommendation IV evidence I a- meta-analysis of RCTs trials, I b- at least one RCT. II a - at least one controlled study without randomization II b - at least one other type of quasi- experimental study non-experimental descriptive studies, such as comparative studies, correlation studies and case control studies from expert committee reports or opinions and/or clinical experience of respected authorities • GPP Good practice point : The view of the Guideline Development Group •The design of a quasi-experiment relates to a particular type of experiment or other study in which one has little or no control over the allocation of the treatments or other factors being studied.
  • 69. 1-Semen analysis • CASA is not superior to conventional semen analysis (Grade A) • Screening for antisperm antibodies should not be offered because there is no evidence of effective treatment to improve fertility. (GPP)
  • 70. What To Do if Semen analysis Is Abnormal?  Repeat confirmatory test ( 3 months after the initial analysis & ttt). (Grade B).  If azoospermia or severe oligozoospermia , repeat test as soon as possible. (GPP)
  • 71. Where & When Testicular Biopsy (TB) be done In Azoospermia? TB should be performed only in a tertiary service where there are facilities for  Sperm recovery ,  Cryopreservation and  ART( C )
  • 72. 2-Assessment of Ovulation  Women with regular monthly menstrual cycles are likely to be ovulating. (Grade B)  The use of basal body temperature charts to confirm ovulation does not reliably predict ovulation and is not recommended. (Grade B)
  • 73. Assessment of Ovulation  Women with regular menstrual cycles and more than 1 year’s infertility are offered a blood test to measure serum progesterone in the mid-luteal phase of their cycle (day 21 of a 28-day cycle) to confirm ovulation. (Grade B)
  • 74. Assessment of Ovulation  Ovulation is most easily documented by a midluteal phase serum progesterone level, which should be obtained approximately one week before the expected menses.  For a typical 28day cycle, the test would be obtained on day 21. A progesterone level >3 ng/mL is evidence of recent ovulation.
  • 75. Assessment of Ovulation  Women with irregular menstrual cycles should be offered a blood test to measure serum FSH & LH (GPP).  Blood test for prolactin should only be offered to women who have an ovulatory disorder, galactorrhoea or a pituitary tumor. (Grade C)
  • 76. Assessment of Ovulation  Tests of ovarian reserve currently have limited sensitivity and specificity in predicting fertility. However, women who have high levels of gonadotrophins should be informed that they are likely to have reduced fertility. (Grade C)  The value of assessing ovarian reserve using Inhibin B is uncertain and is therefore not recommended. (Grade C)
  • 77. Assessment of Ovulation  Women with possible fertility problems are no more likely than the general population to have thyroid disease and the routine measurement of thyroid function should not be offered.  Estimation of thyroid function should be confined to women with symptoms of thyroid disease. (Grade C).
  • 78. Assessment of Ovulation  Women should not be offered an endometrial biopsy to evaluate the luteal phase as part of the investigation of fertility problems because there is no evidence that medical treatment of luteal phase defect improves pregnancy rates (Grade B).
  • 79. 3-Assessment of tubal factor  Women who are not known to have co- morbidities should be offered HSG to screen for tubal occlusion because this is a reliable test for ruling out tubal occlusion, and it is less invasive and makes more efficient use of resources than laparoscopy. (Grade B).
  • 80. Assessment of tubal factor  Where appropriate expertise is available, screening for tubal occlusion using hysterosalpingo-contrast-ultrasonography should be considered because it is an effective alternative to HSG for women who are not known to have co-morbidities (Grade A)
  • 81. Assessment of tubal factor Women who are thought to have co-morbidities should be offered laparoscopy and dye so that tubal and other pelvic pathology can be assessed at the same time. (Grade B)
  • 82. 4-Assessing uterine abnormalities  Women should not be offered hysteroscopy on its own as part of the initial investigation unless clinically indicated, because the effectiveness of surgical treatment of uterine abnormalities on improving pregnancy rates has not been established. (Grade B)
  • 83. Unnecessary laparoscopy!!!  It is not cost effective to do diagnostic laparoscopy as part of the initial infertility evaluation when: History, and physical examination, TVS, HSG, and Midluteal progesterone are all normal (Grade B)
  • 85. When To Do Laparoscopy For tubal evaluation?  When associated pelvic co morbidities (PID, previous Ectopic, endometriosis ..etc) :evaluation of the pelvis is required. (Grade B)
  • 86. Hysteroscopy has NO role in routine evaluation of infertility
  • 88. Indications of Hysteroscopy as workup of infertility?  Abnormal HSG  When Laparoscopy is indicated as in Unexplained infertility ?  Before IVF in cases of unexplained infertility ?!!!!  After Failed IVF ?
  • 89. No Role for... 1. Postcoital test. 2. Endometrial biopsy 3. Antisperm antibodies 4. Routine cervical cultures 5. Thyroid function ( in absence of symptoms suggestive of of thyroid disease) 6.Prolactin (in absence of galactorrhoea and …)
  • 90. The basic infertility evaluation of all couples consists of:  Semen analysis  Assessment of ovulatory function  Determination of tubal patency and presence or absence of abnormalities of the uterine cavity,usually by HSG.  Diagnostic laparoscopy is indicated for women with suspected endometriosis or pelvic adhesions.  Ovarian reserve is assessed with day 3 (FSH) and estradiol levels in women over 35 years of age and in younger women with risk factors for premature ovarian failure.

Notes de l'éditeur

  1. Figure 3 Flowchart summary of algorithm for diagnosis of male infertility. As detailed in section PICO 2 (Is it necessary for all infertile men to undergo a thorough evaluation?) the first line investigations should include Physical Examination, History and Semen Analysis. Abnormalities in these lead to further investigations. YCMD, Y chromosome microdeletion; CFTR, CF transmembrane conductance regulator.